RNAi-siRNAI-miRNA-shRNA News: Breaking RNAi-siRNAI-miRNA-shRNA News, Comments and Articles. - Page: 3

Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34 / Novel SMARTICLES(R) Technology Used to Deliver First-Ever microRNA Oncology Compound in Clinical Development

BOTHELL, WA -- (Marketwired) -- 05/13/13 -- Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's licensee...

Mirna Therapeutics is First to Advance MicroRNA into the Clinic for Cancer

Phase 1 Clinical Trial of Anticancer Drug MRX34 Underway Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA (miRNA) replacement therapies for cancer, announced today that it has initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer. The Phase 1 trial is being conducted in patie...

Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34

BOTHELL, WA -- (Marketwired) -- 05/13/13 -- Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's licensee, Mirna Therapeutics, has reported that they have initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into a human clinical trial for cancer. The Phase 1 trial is being conducted in...

Arrowhead Reports Fiscal 2013 Second Quarter Financial Results

- Conference Call Today at 4:30 p.m. Eastern Time Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced financial results for its fiscal 2013 second quarter ended March 31, 2013. The company is hosting a conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss results. To participate, pleas...

[Arrowhead Research] nets $35.4mm through common and preferred stock offering

With a $9.6mm investment, RA Capital has led a $35.4mm offering by [Arrowhead Research Corp.] (targeted drug delivery of peptide-drug conjugates and RNAi therapeutics for cancer, obesity, and HBV) of common and convertible preferred stock.

RXi Pharmaceuticals to Present at IBC's 15th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference

WESTBOROUGH, Mass., May 9, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQB: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today  announced that the Company's Chief Development Officer, Pamela Pavco, Ph.D., will be presenting at IBC's 15th A...

Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 2013 Bank of America Merrill Lynch Health Care Conference on Thursday, May 16, 2013 at 8:40 a.m. PT (11:40 a.m. ET) at Encore at the Wynn in Las Vegas. A live audio webcast of the presenta...

Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide Backbone

Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 13/326,433 entitled, “Peptide-Based In Vivo siRNA Delivery System.” The allowed claims specifically protect the use of targeted melittin or...

Alnylam Pharmaceuticals Reports First Quarter 2013 Financial Results

– Continued to Execute on “Alnylam 5x15” Product Strategy, Positioning Company for Data-Rich Period over Next Several Months – – Formed Strategic Alliance with The Medicines Company to Develop and Commercialize ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia – – Completed Successful Pub...

Arrowhead Closes $36 Million Private Offering

Financing led by RA Capital with a syndicate of healthcare specialist investors Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that on May 3, 2013 it closed a previously announced private offering of common and convertible preferred stock with gross proceeds of $36 million. The financin...

The microRNA miR-235 couples blast-cell quiescence to the nutritional state

The coordination of stem- and blast-cell behaviours, such as self-renewal, differentiation and quiescence, with physiological changes underlies growth, regeneration and tissue homeostasis. Germline stem and somatic blast cells in newly hatched Caenor...

The shaping and functional consequences of the microRNA landscape in breast cancer

MicroRNAs (miRNAs) show differential expression across breast cancer subtypes, and have both oncogenic and tumour-suppressive roles. Here we report the miRNA expression profiles of 1,302 breast tumours with matching detailed clinical annotation, long...

ADAR1 As Gene-Silencing Modular RNA Multitool

RNA, once considered a bit player in the grand scheme by which genes encode protein, is increasingly seen to have a major role in human genetics. In a study presented in the journal Cell, researchers from The Wistar Institute discovered how the RNA-e...

The targeting and functions of miRNA-383 are mediated by FMRP during spermatogenesis

Arrowhead to Report Fiscal 2013 Second Quarter Financial Results

- Conference Call Scheduled for Thursday, May 9, 2013 - Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced that it will report its financial results for the fiscal 2013 second quarter ended March 31, 2013, on Thursday, May 9, 2013, at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conf...

EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2

MicroRNAs (miRNAs) are generated by two-step processing to yield small RNAs that negatively regulate target gene expression at the post-transcriptional level. Deregulation of miRNAs has been linked to diverse pathological processes, including cancer....

Learn molecular biology from renowned professors and industry leaders at the 2013 Smith College Molecular Biology Summer Workshops, sponsored by New England Biolabs

IPSWICH, Mass. and NORTHAMPTON, Mass., May 1, 2013 /PRNewswire/ -- This summer, Smith College is hosting the 28th annual Molecular Biology Summer Workshops at the Ford Science Center in Northampton, MA.  In cooperation with New England Biolabs (NEB), a leader in the research and development of reagents for the life sciences, Smith College invites interested parties to learn molecular biology...

Announcement - Clontech Laboratories, Inc. Releases the SMARTer® Universal Low Input RNA Kit for Sequencing

MOUNTAIN VIEW, Calif., May 1, 2013 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the SMARTer Universal Low Input RNA Kit for Sequencing. The SMARTer Universal Low Input RNA Kit extends Clontech's NGS (Next Generation Sequencing) solutions to include low input samples of compromised RNA. It combines Clontech's patented SMAR...

RXi Pharmaceuticals to Present at the 2013 ARVO Annual Meeting

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company will be presenting an overview of the use of sd-rxRNAs® in the eye and highlighting specifically RXi’s work...

SMaRT Therapeutics Announces Appointment of Dr. John H. Abeles to the Advisory Board

JUPITER, Fla., April 30, 2013 /PRNewswire/ -- SMaRT Therapeutics, Inc., a leading biotechnology company focused on the development of small-molecule drugs that target and modulate RNA, announced the appointment of Dr. John H. Abeles to its Advisory Board.  Dr. Abeles has had a long and distinguished career in the biotechnology and pharmaceutical industries.  He practiced medicine...

Ascletis Gains China Market Rights from Janssen to a Clinical Stage HIV Protease Inhibitor

HANGZHOU, China and RESEARCH TRIANGLE PARK, N.C., April 30, 2013 /PRNewswire/ -- Ascletis today announced that the company has licensed development, manufacturing and commercialization rights from Janssen R&D Ireland to TMC310911, a next-generation HIV protease inhibitor (PI). The agreement provides Ascletis with exclusive rights to develop and commercialize TMC310911 in Greater China, includi...

Arrowhead Prices $36 Million Private Offering

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has priced a private offering with gross proceeds expected to be $36 million. The offering was priced at $1.83 per common share. Approximately 14.3 million shares of common stock and 9,900 shares of series B convertible preferred stock are expec...

Alnylam to Webcast Conference Call Discussing First Quarter 2013 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the first quarter ending March 31, 2013 on Monday, May 6, 2013, after the U.S. financial markets close. Management will provide an update on the company, discuss first quarter results, and discuss expe...

RXi Pharmaceuticals Announces Investor and Analyst Symposium

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it will hold its first Investor and Analyst Symposium. During this meeting, the company Management and members of...

Selection of optimal combinations of target genes for therapeutic multi-gene silencing based on miRNA co-regulation